Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway

2017 ◽  
Vol 403 ◽  
pp. 305-317 ◽  
Author(s):  
Zhenyu Zhong ◽  
Mengge Huang ◽  
Mengxin Lv ◽  
Yunfeng He ◽  
Changzhu Duan ◽  
...  
2019 ◽  
Vol 145 (8) ◽  
pp. 2170-2181 ◽  
Author(s):  
Ming Sun ◽  
Wenyan Zhao ◽  
Zhaofu Chen ◽  
Ming Li ◽  
Shuqiang Li ◽  
...  

2018 ◽  
Vol 234 (4) ◽  
pp. 3887-3896 ◽  
Author(s):  
Zhihua Zeng ◽  
Wanming Zhou ◽  
Lingxing Duan ◽  
Jian Zhang ◽  
Xiongbing Lu ◽  
...  

2019 ◽  
Vol 20 (4) ◽  
pp. 861 ◽  
Author(s):  
Dongsong Nie ◽  
Jiewen Fu ◽  
Hanchun Chen ◽  
Jingliang Cheng ◽  
Junjiang Fu

MicroRNA-34a (miR-34a), a tumor suppressor, has been reported to be dysregulated in various human cancers. MiR-34a is involves in certain epithelial-mesenchymal transition (EMT)-associated signal pathways to repress tumorigenesis, cancer progression, and metastasis. Due to the particularity of miR-34 family in tumor-associated EMT, the significance of miR-34a is being increasingly recognized. Competing endogenous RNA (ceRNA) is a novel concept involving mRNA, circular RNA, pseudogene transcript, and long noncoding RNA regulating each other’s expressions using microRNA response elements to compete for the binding of microRNAs. Studies showed that miR-34a is efficient for cancer therapy. Here, we provide an overview of the function of miR-34a in tumor-associated EMT. ceRNA hypothesis plays an important role in miR-34a regulation in EMT, cancer progression, and metastasis. Its potential roles and challenges as a microRNA therapeutic candidate are discussed. As the negative effect on cancer progression, miR-34a should play crucial roles in clinical diagnosis and cancer therapy.


2020 ◽  
Vol Volume 13 ◽  
pp. 813-825 ◽  
Author(s):  
Shun Gao ◽  
Hubin Yin ◽  
Hang Tong ◽  
Kai Zhan ◽  
Guang Yang ◽  
...  

2018 ◽  
Vol 17 (1) ◽  
Author(s):  
Hongwei Liu ◽  
Junming Bi ◽  
Wei Dong ◽  
Meihua Yang ◽  
Juanyi Shi ◽  
...  

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Hongwei Liu ◽  
Junming Bi ◽  
Wei Dong ◽  
Meihua Yang ◽  
Juanyi Shi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document